| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Rosalio Madrigal
Cynthia McLaughlin
Michael Rose
| Share Statistics | TRAX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,617.9 | $288.9 | 51% |
|
| Shares Out (Mil) | 35.0 | 54.0 | 40% |
|
| Institutional Ownership | 97.6% | 93.1% | 75% |
|
| Float (Mil) | na | 41.4 | na |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 608 | 480 | 63% |
|
| Price Change (52-week) |
na | 59.9% | na |
|
| Growth | TRAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.881) | ($4.061) | ($3.665) | |
| Month Ago EPS | ($0.787) | ($3.603) | ($3.225) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.778) | ($3.600) | ($3.175) | |
| Year/Year Chg | (7.6%) | na | na | |
| Financials | TRAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($160) | ($43) | 8% |
|
| EPS (TTM) | ($4.530) | ($1.500) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($124) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($149) | $2 | 12% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $1,377 | $190 | 44% |
|
| Valuation | TRAX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.49 | 2.84 | 89% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TRAX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (175.1%) | (47.7%) | 2% |
|
| ROE | (189.9%) | (55.0%) | 4% |
|
| Liabilities to Assets | 7.8% | 29.6% | 4% |
|
| F-Score | 1 | 3 | na |
|
First Tracks Biotherapeutics, Inc. did not pass any screens on 9/2/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
